Combocef 100 Tablet
Cefpodoxime + Clavulanic Acid
100mg + 62.5mg
ACI Limited
| Pack size | 12's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 30.09 AED |
Available as:
Indications
Combocef 100 Tablet is used for:
Pharyngitis, Acute otitis media, Community-acquired pneumonia, Sinusitis, UTI, Cystitis, Gonorrhea, Skin and skin structure infections, Tonsillitis, Respiratory tract infections, Acute Maxillary Sinusitis, Acute bacterial exacerbation of chronic bronchitis, Enteric fever
Adult Dose
Acute Bronchitis & Acute Exacerbations of Chronic Bronchitis, Acute Maxillary Sinusitis
200 mg PO q12hr for 10 days
Acute Community-Acquired Pneumonia
200 mg PO q12hr for 14 days
Pharyngitis/Tonsillitis
100 mg PO q12hr for 5-10 days
Skin/Skin Structure Infections
200-400 mg PO q12hr for 7-14 days
Uncomplicated gonorrhoea
200 mg as a single dose
Uncomplicated Urinary Tract Infections
100 mg PO q12hr for 7-14 days
Complicated urinary tract infections
200 mg PO 12 hourly for 7 days
Child Dose
Child :
2 months to 12 years- 10 mg/kg/day in divided dose, every 12 hours.
Max 400 mg/day q12h
Renal Dose
Renal impairment: Patients on haemodialysis: Dose should be given after each dialysis session.
CrCl (ml/min) Dosage Recommendation
10-39 Increase dosing intervals to 24 hrly.
<10 Increase dosing intervals to 48 hrly.
Administration
Should be taken with food. Take after meals.
Contra Indications
Hypersensitivity.
Precautions
Reduce dosage by 50% if CrCl is 10-30 mL/min and by 75% if CrCl is <10 mL/min (high dosages may cause CNS toxicity)
Bacterial or fungal overgrowth of nonsusceptible organisms may occur with prolonged or repeated therapy
Use with caution in patients with history of penicillin allergy
Use caution in patients with history of beta-lactam allergy, especially IGE mediated reactions, including angioedema, anaphylaxis, urticaria)
Some dosage forms may contain the metabolite of benzyl alcohol benzoic acid; large amounts of benzyl alcohol associated with potentially fatal toxicity (gasping syndrome) in neonates; avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates
Pregnancy-Lactation
Pregnancy category: B
Lactation: Drug excreted in breast milk in low concentrations; not recommended
Interactions
Antacids: Concomitant administration of high doses of antacids (sodium bicarbonate and aluminum hydroxide) or H2 blockers reduces peak plasma levels by 24% to 42% and the extent of absorption by 27% to 32%, respectively. The rate of absorption is not altered by these concomitant medications. Oral anti cholinergics (e.g., propantheline) delay peakn plasma levels (47% increase in Tmax), but do not affect the extent of absorption (AUC).
Probenecid: As with other beta-lactam antibiotics, renal excretion of cefpodoxime was inhibited by probenecid and resulted in an approximately 31% increase in AUC and 20% increase in peak cefpodoxime plasma levels.
Nephrotoxic drugs: Although nephrotoxicity has not been noted when cefpodoxime proxetil was given alone, close monitoring of renal function is advised when cefpodoxime proxetil is administered concomitantly with compounds of known nephrotoxic potential.
Potentially Fatal: Monitor renal function during admin. Additive nephrotoxic effects with furosemide.
Contraindicated (0)
Serious (3)
BCG vaccine live
cholera vaccine
microbiota oral
Adverse Effects
Side effects of Cefpodoxime + Clavulanic Acid :
>10%
Diarrhea in infants and toddlers (15.4%),Diaper rash (12.1%)
1-10%
Diarrhea (7.4%),Nausea (3.8%),Vaginal infection (3.1%),Vomiting (1.1-2.1%),Abdominal pain (1.6%),Rash (1.4%),Headache (1.1%)
Potentially Fatal: Pseudomembranous colitis; nephrotoxicity.
Mechanism of Action
Cefpodoxime binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Addition of clavulanate inhibits beta-lactamase-producing bacteria; Clavulanic acid has a high affinity for and binds to certain ?-lactamases that generally inactivate Cefpodoxime by hydrolyzing its ?-lactam ring. Combining clavulanate potassium with Cefpodoxime extends the antibacterial spectrum of Cefpodoxime to include many bacteria normally resistant to Cefpodoxime and other penicillins and cephalosporins.
Note
Combocef 100 100mg + 62.5mg Tablet manufactured by ACI Limited. Its generic name is Cefpodoxime + Clavulanic Acid. Combocef 100 is availble in Bangladesh.
Farmaco BD drug index information on Combocef 100 Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.